Try it
Pharmacology · Cardiovascular drugs: vericiguat
Sample itemA patient with heart failure and reduced ejection fraction is admitted again despite optimal therapy. Vericiguat is added. What is its mechanism of action?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. Direct stimulation of soluble guanylate cyclase, enhancing nitric oxide signalling and raising cGMP
Vericiguat stimulates soluble guanylate cyclase both directly and by sensitising it to nitric oxide, raising cGMP in vascular smooth muscle and myocardium. It lowers cardiovascular death and heart failure hospitalisation after a worsening event. It is contraindicated in pregnancy and with other soluble guanylate cyclase stimulators such as riociguat.
Option by option
A. Inhibition of neprilysin, raising natriuretic peptide levels
Neprilysin inhibition is the action of sacubitril.
B. Blockade of the If current in the sinus node
If current blockade is the action of ivabradine.
C. Direct stimulation of soluble guanylate cyclase, enhancing nitric oxide signalling and raising cGMP (correct)
Correct. Vericiguat is a soluble guanylate cyclase stimulator.
D. Inhibition of the sodium-glucose cotransporter in the proximal tubule
SGLT2 blockade is the action of dapagliflozin and empagliflozin.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More Pharmacology questions
- Emergency drugsA patient develops stridor, wheeze and hypotension minutes after an injection. What is t…
- AntiepilepticsWhat is the preferred first-line drug for a patient in generalised convulsive status epi…
- AntimicrobialsWhich drug can cause a disulfiram-like reaction when taken with alcohol?
- AntiepilepticsWhich drug is preferred for uncomplicated childhood absence seizures?